Evidence map›Paper›PMID 24745679›Full record

ReviewImmunology and allergy clinics of North America2014

Eosinophilia in mast cell disease.

Anna Kovalszki, Peter F Weller

Abstract readReview
In one paragraph

Review in Immunology and allergy clinics of North America, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 40 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Mastocytosis: from a Molecular Point of View.Clinical reviews in allergy & immunology · 2018
    Review
  7. Eosinophilia.Primary care · 2016
    Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Anna KovalszkiDivision of Allergy and Inflammation, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Boston, MA 02215, USA. Electronic address: akovalsz@bidmc.harvard.edu.
Peter F WellerDivision of Allergy and Inflammation, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue CLS943, Boston, MA 02215, USA; Division of Infectious Diseases, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue CLS943, Boston, MA 02215, USA.
Beth Israel Deaconess Medical Center · USHarvard University · US

Funding

CYTOPLASMIC LIPID BODIES OF INFLAMMATORY CELLSR01AI022571 · NIAID · BETH ISRAEL DEACONESS MEDICAL CENTER · PI WELLER, PETER F · 1985 to 2013
$4.5M
Human Eosinophils: Mechanisms of FunctioningR37AI020241 · NIAID · BETH ISRAEL DEACONESS MEDICAL CENTER · PI WELLER, PETER F · 2010 to 2019
$4.5M
HUMAN EOSINOPHILS: MECHANISMS OF FUNCTIONINGR01AI020241 · NIAID · BETH ISRAEL DEACONESS MEDICAL CENTER · PI WELLER, PETER F · 1985 to 2009
$3.5M
NIAID NIH HHS R01 AI020241NIAID NIH HHS R01 AI022571NIAID NIH HHS R37 AI020241
6 · The paper itself

Abstract

Eosinophils and mast cells coexist in clonal and nonclonal disorders. The interplay between these cells is complex and not fully understood. Discussed are both allergic/nonclonal disorders in which both cell types are increased in number are likely to play a role in pathogenesis and clonal disorders in which both cell types are affected and play key roles in pathogenesis. Finally, some treatment options, keeping both disorders in mind, are discussed. Future directions in thinking about these disorders are also briefly explored.

Indexed as

Gene Expression Regulation, NeoplasticAntineoplastic AgentsBenzamidesBone MarrowCell CommunicationEosinophilsHumansHypereosinophilic SyndromeImatinib MesylateMast CellsMastocytosis, SystemicmRNA Cleavage and Polyadenylation FactorsOncogene Proteins, FusionPiperazinesProtein Kinase InhibitorsProto-Oncogene Proteins c-kitAntineoplastic AgentsBenzamidesFIP1L1-PDGFRA fusion protein, humanImatinib MesylatemRNA Cleavage and Polyadenylation FactorsOncogene Proteins, FusionPiperazinesProtein Kinase InhibitorsProto-Oncogene Proteins c-kitPyrimidinesReceptor, Platelet-Derived Growth Factor alphaStem Cell FactorChronic eosinophilic leukemia (CEL)EosinophiliaFIP1L1-PDGFRA fusionHypereosinophilic syndromeImatinibSystemic mastocytosisTryptase

Identifiers

PMID24745679
PMCPMC4083463
OpenAlexW2126394283

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.